Abstract：Objective: To investigate the relationship between pulmonary arterial hypertension (PH) and plasma levels of N terminal B type brain natriuretic peptide (NT-proBNP) in patients with chronic obstructive pulmonary disease (COPD). Methods: 120 cases of patients with COPD treated in our hospital were selected as the study objects, and 60 cases of acute exacerbation of COPD patients were as group A, the other 60 cases of COPD patients complicated with PH were as group B. At the same time, pulmonary systolic pressure (PASP) was detected in group B, and grouped according to the test results. PASP level less than 30mmHg were as the control group, between 30mmHg and 50mmHg were as the mild group, and more than or equal to 50mmHg were as the moderate and severe group. Plasma NT-proBNP levels and correlation with PH were observed and recorded of all the study objects. Results: Plasma NT-proBNPC level in group B was much higher than that in group A (P< 0.05). The level of NT-proBNP in moderate and severe group was significantly higher than that in the control group and the mild group, with statistically significant differences between every two groups of the three groups (P< 0.05). Plasma NT-proBNP level was positively correlated with PASP (P< 0.05). Conclusion: NT-proBNP level is positively correlated with the severity of PH, and it has certain reference value in judging the severity of PH.
[1] Buchan A,Bennett R,Coad A,et al.The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD[J].Open Heart,2015,2(1):e000052. [2] 魏龙,李峰,秦勇,等.慢性阻塞性肺疾病并发肺动脉高压与血尿酸水平的相关性研究[J].中国现代医学杂志,2014,26(22):90~93. [3] 孟凡祥.法舒地尔治疗慢性阻塞性肺疾病合并肺动脉高压对NT-proBNP的影响[J].解放军医药杂志,2016,28(6):97~100. [4] 吴艳,汪家坤,范晓东,等.血清NT-proBNP、D-二聚体及血气分析与老年慢性阻塞性肺疾病急性加重合并肺动脉高压患者的相关性[J].中国老年学杂志,2015,35(19):5550~5551. [5] 慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67~80. [6] Sharif-Kashani B,Hamraghani A,Salamzadeh J,et al.The effect of amlodipine and sildenafil on the NT-ProBNP level of patients with COPD-induced pulmonary hypertension[J].Iranian Journal of Pharmaceutical Research:IJPR,2014,13(Suppl):161~168. [7] 董丽,姚福军,陈贺,等.慢性阻塞性肺疾病缓解期患者血浆N-端脑钠肽前体和超敏C反应蛋白与肺动脉高压相关性研究[J].中国医刊,2014,49(2):49~50. [8] 王娜娜,孟自力,陈亮,等.慢性阻塞性肺疾病并发肺动脉高压血清标志物研究[J].临床肺科杂志,2016,21(6):1051~1055. [9] 吕宗军.血浆NT-proBNP对慢性阻塞性肺疾病合并肺心病的鉴别诊断价值[J].心脑血管病防治,2014,14(5):403~405. [10] 何淑娟,裴素莉,彭莉丽.N-端脑钠肽前体在慢性阻塞性肺疾病中的变化及意义[J].实用临床医药杂志,2013,17(24):35~37,44. [11] Lee M H S,Chang C L,Davies A R,et al.Cardiac dysfunction and N‐terminal pro‐B‐type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease[J].Internal Medicine Journal,2013,43(5):595~598. [12] 张立涛,许宁,李素彦,等.慢性阻塞性肺疾病急性加重期患者血浆N端脑利钠肽前体水平的变化及应用价值[J].河北医药,2014,36(22):3385~3387
2017, Vol. 23 
冀公网安备13080202000677号